August 27, 2018 / 4:35 PM / 8 months ago

U.S. FDA proposes restricting compounding of three drug substances

Aug 27 (Reuters) - The U.S. Food and Drug Administration on Monday in a first-of-its-kind action proposed restricting the ability of companies that produce compounded medications in bulk from using three substances that are active ingredients in FDA-approved drugs.

The three substances include vasopressin, the active ingredient in Endo International Plc’s blood pressure drug Vasostrict, which has been the subject of a lawsuit targeting how the FDA regulates drug compounding. (Reporting by Nate Raymond in Boston)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below